SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains […]
Hain Celestial To Participate in Upcoming Investor Conferences
HOBOKEN, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) — Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company […]
Dillard’s, Inc. to Report Third Quarter and Year-to-Date Results
LITTLE ROCK, Ark., Nov. 13, 2024 (GLOBE NEWSWIRE) — Dillard’s, Inc. (DDS: NYSE) will announce results for the 13 and […]
KULR Reports Record Revenue for the Third Quarter of 2024
HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global […]
Victoria’s Secret & Co. Invites You to Listen to the Third Quarter 2024 Earnings Call Webcast
REYNOLDSBURG, Ohio, Nov. 13, 2024 (GLOBE NEWSWIRE) — In conjunction with the Victoria’s Secret & Co. (NYSE: VSCO) third quarter […]
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” […]
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at […]
Alpine Income Property Trust Announces Changes to Board of Directors
WINTER PARK, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”) […]
Lulus Reports Third Quarter 2024 Results
Significant Sequential Quarterly Net Revenue Comp Improvement with Q3 Reaching Negative Low Single Digits Updated Outlook for Q4 and Fiscal […]
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition […]
